Monoclonal Antibody Pharmacokinetics and Pharmacodynamics

Therapeutic Monoclonal Antibodies: From Bench to Clinic

Volumn , Issue , 2009, Pages 439-460

  Gibson, Christopher R ^a   Sandhu, Punam ^a   Hanley, William D ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Drug drug interactions affecting pharmacokinetics administration of monoclonal antibodies; Monoclonal antibody pharmacokinetics and pharmacodynamics; Pharmacokinetic pharmacodynamic relationships

Indexed keywords

EID: 79952654246     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470485408.ch19     Document Type: Chapter

References (69)

1. Bauer, R.J., R.L. Dedrick, M.L. White, M.J. Murray, and M.R. Garovoy. 1999. Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis. J. Pharmacokinet. Biopharm. 27(4):397-420.
2. Baumann, A. 2006. Early development of therapeutic biologics: Pharmacokinetics. Curr. Drug Metab. 7(1): 15-21.
3. Baxter, L.T., H. Zhu, D.G. Mackensen, and R.K. Jain. 1994. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res. 54(6):1517-1528.
4. Brambell, F.W., W.A. Hemmings, and I.G. Morris. 1964. A theoretical model of gamma-globulin catabolism. Nature 203:1352-1354.
5. Busse, W., J. Corren, B.Q. Lanier, et al. 2001. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J. Allergy Clin. Immunol. 108(2):184-190.
6. Casale, T.B., I.L. Bernstein, W.W. Busse, et al. 1997. Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J. Allergy Clin. Immunol. 100(1):110-121.
7. Cunningham, D., Y. Humblet, S. Siena, et al. 2004. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351(4):337-345.
8. Daeron, M. 1997. Fc receptor biology. Annu. Rev. Immunol. 15:203-234.
9. Dall'Acqua, W.F., R.M. Woods, E.S. Ward, et al. 2002. Increasing the affinity of a human IgG1 for the neonatal Fc receptor: bBiological consequences. J. Immunol. 169(9):5171-5180.
10. Danilov, S.M., V.D. Gavrilyuk, F.E. Franke, et al. 2001. Lung uptake of antibodies to endothelial antigens: Key determinants of vascular immunotargeting. Am. J. Physiol. Lung Cell. Mol. Physiol. 280(6):L1335-L1347.
11. Datta-Mannan, A., D.R. Witcher, Y. Tang, J. Watkins, W. Jiang, and V.J. Wroblewski. 2007. Humanized IgG1 variants with differential binding properties to the neonatal Fc receptor: Relationship to pharmacokinetics in mice and primates. Drug Metab. Dispos. 35(1):86-94.
12. Davies, K.A., P.T. Chapman, P.J. Norsworthy, et al. 1995. Clearance pathways of soluble immune complexes in the pig. Insights into the adaptive nature of antigen clearance in humans. J. Immunol. 155(12):5760-5768.
13. Davies, K.A., V. Hird, S. Stewart, et al. 1990. A study of in vivo immune complex formation and clearance in man. J. Immunol. 144(12):4613-4620.
14. Delacroix, D.L., H.J. Hodgson, A. McPherson, C. Dive, and J.P. Vaerman. 1982. Selective transport of polymeric immunoglobulin A in bile. Quantitative relationships of monomeric and polymeric immunoglobulin A, immu-noglobulin M, and other proteins in serum, bile, and saliva. J. Clin. Invest. 70(2):230-241.
15. Fahy, J.V., D.W. Cockcroft, L.P. Boulet, et al. 1999. Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects. Am. J. Respir. Crit. CareMed. 160(3):1023-1027.
16. Fox, J.A., T.E. Hotaling, C. Struble, J. Ruppel, D.J. Bates, and M.B. Schoenhoff. 1996. Tissue distribution and complex formation with IgE of an anti-IgE antibody after intravenous administration in cynomolgus monkeys. J. Pharmacol. Exp. Ther. 279(2):1000-1008.
17. Ghetie, V., J.G. Hubbard, J.K. Kim, M.F. Tsen, Y. Lee, and E.S. Ward. 1996. Abnormally short serum half-lives of IgG in beta 2-microglobulin-deficient mice. Eur. J. Immunol. 26(3):690-696.
18. Ghetie, V., and E.S. Ward. 2002. Transcytosis and catabolism of antibody. Immunol. Res. 25(2):97-113.
19. Gillies, S.D., K.M. Lo, C. Burger, Y. Lan, T. Dahl, and W.K. Wong. 2002. Improved circulating half-life and efficacy of an antibody-interleukin 2 immunocytokine based on reduced intracellular proteolysis. Clin. CancerRes. 8(1):210-216.
20. Gordon, M.S., K. Margolin, M. Talpaz, et al. 2001. PhaseI safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 19(3):843-850.
21. Gottlieb, A.B., J.G. Krueger, K. Wittkowski, R. Dedrick, P.A. Walicke, and M. Garovoy. 2002. Psoriasis as a model for T-cell-mediated disease: Immunobiologic and clinical effects of treatment with multiple doses of efalizu-mab, an anti-CD11a antibody. Arch. Dermatol. 138(5):591-600.
22. Guarino, A., R.B. Canani, S. Russo, et al. 1994. Oral immunoglobulins for treatment of acute rotaviral gastroenteritis. Pediatrics 93(1):12-16.
23. Gurbaxani, B., L.L. Dela Cruz, K. Chintalacharuvu, and S.L. Morrison. 2006. Analysis of a family of antibodies with different half-lives in mice fails to find a correlation between affinity for FcRn and serum half-life. Mol. Immunol. 43(9):1462-1473.
24. Hart, P.H. 2001. Regulation of the inflammatory response in asthma by mast cell products. Immunol. Cell Biol. 79(2):149-153.
25. Hinton, P.R., J.M. Xiong, M.G. Johlfs, M.T. Tang, S. Keller, and N. Tsurushita. 2006. An engineered human IgG1 antibody with longer serum half-life. J. Immunol. 176(1):346-356.
26. Hwang, W.Y., and J. Foote. 2005. Immunogenicity of engineered antibodies. Methods 36(1):3-10.
27. Israel, E.J., D.F. Wilsker, K.C. Hayes, D. Schoenfeld, and N.E. Simister. 1996. Increased clearance of IgG in mice that lack beta 2-microglobulin: Possible protective role of FcRn. Immunology 89(4):573-578.
28. Joshi, A., R. Bauer, P. Kuebler, et al. 2006. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: A monoclonal antibody approved for use in psoriasis. J. Clin. Pharmacol. 46(1):10-20.
29. Kereiakes, D.J., J.P. Runyon, N.S. Kleiman, et al. 1996. Differential dose-response to oral xemilofiban after antecedent intravenous abciximab. Administration for complex coronary intervention. Circulation 94(5):906-910.
30. Kim, J.K., M.F. Tsen, V. Ghetie, and E.S. Ward. 1994. Identifying amino acid residues that influence plasma clearance of murine IgG1 fragments by site-directed mutagenesis. Eur. J. Immunol. 24(3):542-548.
31. Kovarik, J.M., M.D. Pescovitz, H.W. Sollinger, et al. 2001. Differential influence of azathioprine and mycopheno-late mofetil on the disposition of basiliximab in renal transplant patients. Clin. Transplant. 15(2):123-130.
32. Krueger, J.G. 2002. The immunologic basis for the treatment of psoriasis with new biologic agents. J. Am. Acad. Dermatol. 46(1):1-23; quiz 23-26.
33. Kuus-Reichel, K., L.S. Grauer, L.M. Karavodin, C. Knott, M. Krusemeier, and N.E. Kay. 1994. Will immunogeni-city limit the use, efficacy, and future development of therapeutic monoclonal antibodies? Clin. Diagn. Lab. Immunol. 1(4):365-372.
34. Leslie, R.G. 1982. Macrophage interactions with antibodies and soluble immune complexes. Immunobiology 161(3-4):322-333.
35. Lin, Y.S., C. Nguyen, J.L. Mendoza, et al. 1999. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J. Pharmacol. Exp. Ther. 288(1):371-378.
36. Lobo, E.D., R.J. Hansen, and J.P. Balthasar. 2004. Antibody pharmacokinetics and pharmacodynamics. J. Pharm. Sci. 93(11):2645-2668.
37. Losonsky, G.A., J.P. Johnson, J.A. Winkelstein, and R.H. Yolken. 1985. Oral administration of human serum immunoglobulin in immunodeficient patients with viral gastroenteritis. A pharmacokinetic and functional analysis. J. Clin. Invest. 76(6):2362-2367.
38. Mahmood, I. 1999. Allometric issues in drug development. J. Pharm. Sci. 88(11):1101-1106.
39. Mahmood, I., and M.D. Green. 2007. Drug interaction studies of therapeutic proteins or monoclonal antibodies. J. Clin. Pharmacol. 47(12):1540-1554.
40. Maini, R.N., F.C. Breedveld, J.R. Kalden, et al. 1998. Therapeutic efficacy of multiple intravenous infusions of antitumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 41(9):1552-1563.
41. Meier, W., A. Gill, M. Rogge, et al. 1995. Immunomodulation by LFA3TIP, an LFA-3/IgG1 fusion protein: Cell line dependent glycosylation effects on pharmacokinetics and pharmacodynamic markers. Therap. Immunol. 2(3):159-171.
42. Meno-Tetang, G.M., and P.J. Lowe. 2005. On the prediction of the human response: A recycled mechanistic pharmacokinetic/pharmacodynamic approach. Basic Clin. Pharmacol. Toxicol. 96(3):182-192.
43. Molthoff, C.F., H.M. Pinedo, H.M. Schluper, H.W. Nijman, and E. Boven. 1992. Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab')2 fragments in experimental ovarian cancer. Br. J. Cancer 65(5):677-683.
44. Mordenti, J., S.A. Chen, J.A. Moore, B.L. Ferraiolo, and J.D. Green. 1991. Interspecies scaling of clearance and volume of distribution data for five therapeutic proteins. Pharm. Res. 8(11):1351-1359.
45. Mori, S. 2007. A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: Characterization of infliximab-resistant cases and PK-based modified therapy. Mod. Rheumatol. 17(2):83-91.
46. Mould, D.R., C.B. Davis, E.A. Minthorn, et al. 1999. A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis. Clin. Pharmacol. Ther. 66(3):246-257.
47. Mould, D.R., and K.R. Sweeney. 2007. The pharmacokinetics and pharmacodynamics of monoclonal antibodies: Mechanistic modeling applied to drug development. Curr. Opin. Drug. Discov. Develop. 10(1):84-96.
48. Nestorov, I. 2005. Clinical pharmacokinetics of TNF antagonists: How do they differ? Semin. Arthritis Rheum. 34(5 Suppl 1):12-18.
49. Ng, C.M., A. Joshi, R.L. Dedrick, M.R. Garovoy, and R.J. Bauer. 2005. Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis. Pharm. Res. 22(7):1088-1100.
50. Owen, C.E. 2002. Anti-immunoglobulin E therapy for asthma. Pulm. Pharmacol. Ther. 15(5):417-424.
51. Pendley, C., A. Schantz, and C. Wagner. 2003. Immunogenicity of therapeutic monoclonal antibodies. Curr. Opin. Mol. Ther. 5(2):172-179.
52. Petkova, S.B., S. Akilesh, T.J. Sproule, et al. 2006. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: Potential application in humorally mediated autoimmune disease. Int. Immunol. 18(12):1759-1769.
53. Rehlaender, B.N., and M.J. Cho. 1998. Antibodies as carrier proteins. Pharm. Res. 15(11):1652-1656.
54. Rojas, J.R., R.P. Taylor, M.R. Cunningham, et al. 2005. Formation, distribution, and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J. Pharmacol. Exp. Ther. 313(2):578-585.
55. Roopenian, D.C., and S. Akilesh. 2007. FcRn: The neonatal Fc receptor comes of age. Nature Rev. Immunol. 7(9):715-725.
56. Scheinfeld, N. 2003. Adalimumab (HUMIRA): A review. J. Drugs Dermatol. 2(4):375-377.
57. Schifferli, J.A., and R.P. Taylor. 1989. Physiological and pathological aspects of circulating immune complexes. KidneyInt. 35(4):993-1003.
58. Seitz, K., and H. Zhou. 2007. Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: Reality check. J. Clin. Pharmacol. 47(9):1104-1118.
59. Sharma, A., C.B. Davis, L.A. Tobia, et al. 2000. Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4. J. Pharmacol. Exp. Ther. 293(1):33-41.
60. Sifontis, N.M., E. Benedetti, and E.M. Vasquez. 2002. Clinically significant drug interaction between basiliximab and tacrolimus in renal transplant recipients. Transplant Proc. 34(5):1730-1732.
61. Sinclair, A.M., and S. Elliott. 2005. Glycoengineering: The effect of glycosylation on the properties of therapeutic proteins. J. Pharm. Sci. 94(8):1626-1635.
62. Strehlau, J., L. Pape, G. Offner, B. Nashan, and J.H. Ehrich. 2000. Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients. Lancet 356(9238):1327-1328.
63. Tabrizi, M.A., C.M. Tseng, and L.K. Roskos. 2006. Elimination mechanisms of therapeutic monoclonal antibodies. Drug Discov. Today 11(1-2):81-88.
64. Tang, L., A.M. Persky, G. Hochhaus, and B. Meibohm. 2004. Pharmacokinetic aspects of biotechnology products. J. Pharm. Sci. 93(9):2184-2204.
65. Ternant, D., and G. Paintaud. 2005. Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin. Biol. Ther. 5 (Suppl 1):S37-S47.
66. Vasquez, E.M., and R. Pollak. 1997. OKT3 therapy increases cyclosporine blood levels. Clin. Transplant. 11(1):38-41.
67. Waldmann, T.A., A. Iio, M. Ogawa, O.R. McIntyre, and W. Strober. 1976. The metabolism of IgE. Studies in normal individuals and in a patient with IgE myeloma. J. Immunol. 117(4):1139-1144.
68. Wu, B., A. Joshi, S. Ren, and C. Ng. 2006. The application of mechanism-based PK/PD modeling in pharmaco-dynamic-based dose selection of muM17, a surrogate monoclonal antibody for efalizumab. J. Pharm. Sci. 95(6):1258-1268.
69. Xu, Y., and M.A. Villalona-Calero. 2002. Irinotecan: Mechanisms of tumor resistance and novel strategies for modulating its activity. Ann. Oncol. 13(12):1841-1851.